Mirtazapin Ratiopharm (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Ratiopharm, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients and may improve mood, sleep and appetite.

GNH USA supplies Mirtazapin Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for mental‑health treatment programs across Europe, Asia and the Americas.

Mirtazapine is an antidepressant that acts on noradrenergic and serotonergic pathways, primarily used for major depressive disorder. - Major Depressive Disorder: alleviates depressive symptoms and improves overall mood. - Depressive Episodes in Bipolar Disorder (adjunct): helps reduce depressive phases when used with mood stabilisers. - Anxiety Associated with Depression: may lessen anxiety symptoms that accompany depressive states.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal ideation, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents - Cardiovascular effects such as orthostatic hypotension

Before prescribing Mirtazapine, clinicians should consider several safety aspects. - Assess hepatic function: evaluate liver enzymes prior to initiation. - Monitor weight: due to potential for significant weight gain. - Screen for suicidal thoughts: particularly during the first weeks of therapy. - Use caution in elderly patients: increased risk of sedation, falls and confusion. - Avoid abrupt discontinuation: taper the dose under medical supervision to minimise withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Alcohol: enhances sedative effects. - Anticholinergic drugs (e.g., diphenhydramine): may increase dry mouth and constipation.